CN1136806A - 脯氨酰肽链内切酶抑制剂 - Google Patents

脯氨酰肽链内切酶抑制剂 Download PDF

Info

Publication number
CN1136806A
CN1136806A CN94194374A CN94194374A CN1136806A CN 1136806 A CN1136806 A CN 1136806A CN 94194374 A CN94194374 A CN 94194374A CN 94194374 A CN94194374 A CN 94194374A CN 1136806 A CN1136806 A CN 1136806A
Authority
CN
China
Prior art keywords
compound
formula
carbonyl
compounds
pentafluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN94194374A
Other languages
English (en)
Chinese (zh)
Inventor
N·P·皮特
J·P·布克哈特
S·米哈迪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Merrell Dow Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharmaceuticals Inc filed Critical Merrell Dow Pharmaceuticals Inc
Publication of CN1136806A publication Critical patent/CN1136806A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D277/06—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pyrrole Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN94194374A 1993-12-02 1994-11-08 脯氨酰肽链内切酶抑制剂 Pending CN1136806A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16110693A 1993-12-02 1993-12-02
US08/161,106 1993-12-02

Publications (1)

Publication Number Publication Date
CN1136806A true CN1136806A (zh) 1996-11-27

Family

ID=22579844

Family Applications (1)

Application Number Title Priority Date Filing Date
CN94194374A Pending CN1136806A (zh) 1993-12-02 1994-11-08 脯氨酰肽链内切酶抑制剂

Country Status (19)

Country Link
US (1) US5661167A (enExample)
EP (1) EP0731788B1 (enExample)
JP (1) JPH09506090A (enExample)
KR (1) KR100341982B1 (enExample)
CN (1) CN1136806A (enExample)
AT (1) ATE223894T1 (enExample)
AU (1) AU684861B2 (enExample)
CA (1) CA2177821C (enExample)
DE (1) DE69431359T2 (enExample)
DK (1) DK0731788T3 (enExample)
ES (1) ES2179093T3 (enExample)
HU (1) HUT74687A (enExample)
IL (1) IL111775A (enExample)
NO (1) NO962238D0 (enExample)
NZ (1) NZ276600A (enExample)
PT (1) PT731788E (enExample)
TW (1) TW280818B (enExample)
WO (1) WO1995015310A1 (enExample)
ZA (1) ZA949302B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859031A (en) 1995-06-07 1999-01-12 Gpi Nil Holdings, Inc. Small molecule inhibitors of rotamase enzyme activity
JP4806628B2 (ja) 2003-05-05 2011-11-02 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤
EP1824846A2 (en) 2003-11-03 2007-08-29 Probiodrug AG Novel compounds for the treatment of neurological disorders
WO2005049027A2 (en) 2003-11-03 2005-06-02 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
KR101099206B1 (ko) 2004-02-05 2011-12-27 프로비오드룩 아게 신규한 글루타미닐 시클라제 저해제
US8278345B2 (en) 2006-11-09 2012-10-02 Probiodrug Ag Inhibitors of glutaminyl cyclase
JP5523107B2 (ja) 2006-11-30 2014-06-18 プロビオドルグ エージー グルタミニルシクラーゼの新規阻害剤
EP2481408A3 (en) 2007-03-01 2013-01-09 Probiodrug AG New use of glutaminyl cyclase inhibitors
WO2008128985A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
WO2008144748A1 (en) * 2007-05-21 2008-11-27 The Uab Research Foundation Prolyl endopeptidase inhibitors for reducing or preventing neutrophilic inflammation
MX2012002993A (es) 2009-09-11 2012-04-19 Probiodrug Ag Derivados heterociclicos como inhibidores de ciclasa glutaminilo.
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
US8269019B2 (en) 2010-03-10 2012-09-18 Probiodrug Ag Inhibitors
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
ES2570167T3 (es) 2011-03-16 2016-05-17 Probiodrug Ag Derivados de benzimidazol como inhibidores de glutaminil ciclasa
CA2938369C (en) 2014-01-28 2019-08-06 Spirit Global Energy Solutions, Inc. Down-hole gas and solids separator utilized in production hydrocarbons
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4518528A (en) * 1983-05-19 1985-05-21 Rasnick David W α Amino fluoro ketones
ZA86746B (en) * 1985-02-04 1986-09-24 Merrell Dow Pharma Novel peptidase inhibitors
DE3712365A1 (de) * 1987-04-11 1988-10-27 Hoechst Ag Neue 2-acylpyrrolidin-derivate, verfahren zu ihrer herstellung, sie enthaltende mittel sowie deren verwendung
US4855303A (en) * 1987-07-01 1989-08-08 Pfizer Inc. Fluorine containing renin inhibitors
JPH0662591B2 (ja) * 1988-12-14 1994-08-17 株式会社ヤクルト本社 新規なチオプロリン誘導体
WO1990012005A1 (fr) * 1989-04-13 1990-10-18 Japan Tobacco Inc. Nouveaux derives aminoacides possedant une activite d'inhibiteur de la prolylendopeptidase

Also Published As

Publication number Publication date
US5661167A (en) 1997-08-26
EP0731788B1 (en) 2002-09-11
DK0731788T3 (da) 2003-01-20
IL111775A0 (en) 1995-01-24
ATE223894T1 (de) 2002-09-15
NZ276600A (en) 1997-09-22
AU1091795A (en) 1995-06-19
CA2177821C (en) 2000-03-28
JPH09506090A (ja) 1997-06-17
DE69431359T2 (de) 2003-07-31
PT731788E (pt) 2003-01-31
HUT74687A (en) 1997-01-28
CA2177821A1 (en) 1995-06-08
KR100341982B1 (ko) 2002-11-30
ES2179093T3 (es) 2003-01-16
EP0731788A1 (en) 1996-09-18
DE69431359D1 (de) 2002-10-17
WO1995015310A1 (en) 1995-06-08
IL111775A (en) 1998-06-15
HU9601472D0 (en) 1996-07-29
AU684861B2 (en) 1998-01-08
NO962238L (no) 1996-05-31
NO962238D0 (no) 1996-05-31
TW280818B (enExample) 1996-07-11
ZA949302B (en) 1995-08-07

Similar Documents

Publication Publication Date Title
US7119073B2 (en) Peptides and their use as inhibitors of hepatitis C virus ns3 protease
US5602253A (en) Peptides derivatives
EP0672658B1 (en) Antithrombotic agents
US5496927A (en) Peptidase inhibitors
US20250188116A1 (en) Deprotection method and resin removal method in solid-phase reaction for peptide compound or amide compound, and method for producing peptide compound
KR100341982B1 (ko) 프롤릴엔도펩티다제억제제
US6515011B2 (en) Thrombin inhibitors
US5639739A (en) Imidazole containing aminoboronic acids
JPH07507069A (ja) ヒトの心臓キマーゼを含むアンギオテンシンｉキマーゼに関する阻害剤
JP4384277B2 (ja) 置換された６−および７−アミノテトラヒドロイソキノリンカルボン酸
CN1168673A (zh) 具有n-末端磺酰基或氨基磺酰基的新颖二肽对-脒基苄基酰胺
JP2004503563A (ja) 凝固因子Ｘａ阻害剤
CN1137134C (zh) 多氟烷基色氨酸三肽凝血酶抑制剂
US5731439A (en) Piperidine containing aminobornic acids
TW419482B (en) Acylated enol derivatives of <alpha>-ketoesters and <alpha>-ketoamides
US4690936A (en) Anti-hypertensive agents
US4833152A (en) Anti-hypertensive agents
JPH0532602A (ja) ナフチルメチルアミン誘導体及びこれを含有するレニン阻害剤
JPH05163287A (ja) ペプチド誘導体
US5389612A (en) Phosphonic peptide inhibitors of bacterial collagenases
JPH01246257A (ja) ３―チオプロピオン酸誘導体の製造法
JPH0925293A (ja) ヒスチジル−ヒドロキサム酸誘導体
WO2011092671A1 (en) Proline derivatives for use in the treatment of diabetes
JPS6059232B2 (ja) エポキシサクシニルアミノ酸誘導体
IE921100A1 (en) Novel compounds

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C01 Deemed withdrawal of patent application (patent law 1993)
WD01 Invention patent application deemed withdrawn after publication